Positions

Overview

  • Lalita Shevde-Samant, Ph.D.,is Associate Director for Education and Training for the O’Neal Comprehensive Cancer Center at UAB and Professor in the Department of Pathology. She also is Director of the Cancer Biology Graduate Theme at UAB. Shevde-Samant received her Ph.D. in Cancer Immunology at the Cancer Research Institute, University of Bombay,India. Following postdoctoral training in the area of metastasis at the Hershey Medical Center, Penn State University and at UAB, she was on faculty at the University of South Alabama beforebeing recruited in 2012 to the Department of Pathology at UAB.

    Over the past 12years, Shevde-Samant has been involved in education, teaching, and academic mentoring in leadership roles that include serving as the Director of the Cancer Biology Theme ofGraduate Schools at two Universities, in addition to serving as a course director for multiple and diverse graduate-level courses. She is actively engaged in training and mentoring graduate students and fellowsand has been honored with the UAB Graduate Dean’s mentoring Award.

    Her international initiative for mentoring the next generation of metastasis investigators includesthe successfullyestablishedEarly Career Ambassadors of Metastasis Research (ECAM) program of the Metastasis Research Society (MRS);ECAM connectsmentees with senior metastasis researchers worldwide, for short sabbaticals, career-development, and leadership skills. She has mentored junior faculty through the American Society for Cell Biology (ASCB) Faculty Research and Education Development (FRED) program and continues to participate in careerdevelopment and mentoring sessions at meetings of the American Association for Cancer Research (AACR) and Cancer Biology Training Consortium (CABTRAC).

    Shevde-Samant leads a research program focused on identifying targetable vulnerabilities of metastatic progression. Her research centers on understanding effects of aberrantly activated developmental signaling on regulating tumor cell intrinsic events such as resistance to DNA damage and metabolic adaptation, and dynamic interactions of tumor cells with their complex microenvironment. Her research is funded through extramural grants from the NCI andthe Department of Defense. Shevde-Samantis a permanent member of the NCI Chemoprevention Study Section (CPSS).
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 Inhibition of Hedgehog signaling reprograms the dysfunctional immune microenvironment in breast cancerOncoImmunology.  8. 2019
    2019 O-GlcNAcylation of GLI transcription factors in hyperglycemic conditions augments Hedgehog activityLaboratory Investigation.  99:260-270. 2019
    2018 Conditional knockout of N-Myc and STAT interactor disrupts normal mammary development and enhances metastatic ability of mammary tumorsOncogene.  37:1610-1623. 2018
    2018 Deficiency of tumor suppressor Merlin facilitates metabolic adaptation by co-operative engagement of SMAD-Hippo signaling in breast cancerCarcinogenesis.  39:1165-1175. 2018
    2017 Biomimetic strategies to recapitulate organ specific microenvironments for studying breast cancer metastasisInternational Journal of Cancer.  141:1091-1109. 2017
    2017 Developing Cures: Targeting Ontogenesis in CancerTrends in Cancer.  3:126-136. 2017
    2017 BH3 mimetics suppress CXCL12 expression in human malignant peripheral nerve sheath tumor cells.Oncotarget.  8:8670-8678. 2017
    2017 Loss of Merlin induces metabolomic adaptation that engages dependence on Hedgehog signalingScientific Reports.  7. 2017
    2017 Genomic regulation of invasion by STAT3 in triple negative breast cancerOncotarget.  8:8226-8238. 2017
    2016 Emerging roles and underlying molecular mechanisms of DNAJB6 in cancerOncotarget.  7:53984-53996. 2016
    2016 Identification of initial leads directed at the calmodulin-binding region on the Src-SH2 domain that exhibit anti-proliferation activity against pancreatic cancerBioorganic and Medicinal Chemistry Letters.  26:1237-1244. 2016
    2016 Erratum to: 'Hedgehog signaling: Modulation of cancer properties and tumor microenvironment' [Hanna and Shevde Molecular Cancer (2016) 15:35] DOI: 10.1186/s12943-016-0522-6Molecular Cancer.  15. 2016
    2016 Hedgehog signaling: Modulation of cancer properies and tumor mircroenvironmentMolecular Cancer.  15. 2016
    2016 Loss of tumor suppressor Merlin results in aberrant activation of Wnt/β-catenin signaling in cancerOncotarget.  7:17991-18005. 2016
    2016 Tamoxifen induces cytotoxic autophagy in glioblastomaJournal of Neuropathology and Experimental Neurology.  75:946-954. 2016
    2015 The impact of hedgehog signaling pathway on DNA repair mechanisms in human cancerCancers.  7:1333-1348. 2015
    2015 N-Myc and STAT Interactor regulates autophagy and chemosensitivity in breast cancer cellsScientific Reports.  5. 2015
    2014 ALDH1A1 maintains ovarian cancer stem cell-like properties by altered regulation of cell cycle checkpoint and DNA repair network signalingPLoS ONE.  9. 2014
    2014 MicroRNA-29 negatively regulates EMT regulator N-myc interactor in breast cancerMolecular Cancer.  13. 2014
    2014 Nonclassical HEDGEHOG-GLI signaling and its clinical implicationsInternational Journal of Cancer.  135:1-6. 2014
    2014 Role of osteopontin in the pathophysiology of cancerCollagen and related research.  37:131-141. 2014
    2014 Loss of N-Myc interactor promotes epithelial-mesenchymal transition by activation of TGF-β/SMAD signalingOncogene.  33:2620-2628. 2014
    2014 GLI1 upregulates C-JUN through a specific 130-kDa isoform.International Journal of Oncology.  44:655-661. 2014
    2014 GLI1 upregulates C-JUN through a specific 130-kDa isoformInternational Journal of Oncology.  44:655-661. 2014
    2014 NMI and EMTOncoscience.  1:476-477. 2014
    2013 Nonclassical activation of Hedgehog signaling enhances multidrug resistance and makes cancer cells refractory to smoothened-targeting Hedgehog inhibitionJournal of Biological Chemistry.  288:11824-11833. 2013
    2012 CD44+/CD24- ovarian cancer cells demonstrate cancer stem cell properties and correlate to survivalClinical and Experimental Metastasis.  29:939-948. 2012
    2012 Merlin: The wizard requires protein stability to function as a tumor suppressorBiochimica et Biophysica Acta (BBA) - Reviews on Cancer.  1826:400-406. 2012
    2012 Sulindac inhibits tumor cell invasion by suppressing NF-κB-mediated transcription of microRNAsOncogene.  31:4979-4986. 2012
    2012 Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repairOncogene.  31:4718-4724. 2012
    2012 DNAJB6 chaperones PP2A mediated dephosphorylation of GSK3β to downregulate β-catenin transcription target, osteopontinOncogene.  31:4472-4483. 2012
    2012 Cytoplasmic translocation of p21 mediates NUPR1-induced chemoresistance: NUPR1 and p21 in chemoresistanceFEBS Letters.  586:3429-3434. 2012
    2012 Micro-RNA-632 downregulates DNAJB6 in breast cancerLaboratory Investigation.  92:1310-1317. 2012
    2012 Increased vascularity and spontaneous metastasis of breast cancer by hedgehog signaling mediated upregulation of cyr61Oncogene.  31:3370-3380. 2012
    2012 DNAJB6 governs a novel regulatory loop determining Wnt/β-catenin signalling activityBiochemical Journal.  444:573-580. 2012
    2012 Cellular stress stimulates nuclear localization signal (NLS) independent nuclear transport of MRJExperimental Cell Research.  318:1086-1093. 2012
    2012 Dickkopf1: A tumor suppressor or metastasis promoter?International Journal of Cancer.  130:1477-1483. 2012
    2012 Hedgehog signaling in tumor cells facilitates osteoblast-enhanced osteolytic metastasesPLoS ONE.  7. 2012
    2012 Targeted inhibition of telomerase activity combined with chemotherapy demonstrates synergy in eliminating ovarian cancer spheroid-forming cellsGynecologic Oncology.  124:598-605. 2012
    2012 CD44+/CD24- ovarian cancer cells demonstrate cancer stem cell-like properties and correlate to survival.Clinical and Experimental Metastasis.  28:400-406. 2012
    2012 The hedgehog pathway conditions the bone microenvironment for osteolytic metastasis of breast cancer.International Journal of Breast Cancer.  2012:298623. 2012
    2012 The influence of the cancer microenvironment on the process of metastasis.International Journal of Breast Cancer.  2012:756257. 2012
    2011 Loss of tumor suppressor merlin in advanced breast cancer is due to post-translational regulationJournal of Biological Chemistry.  286:40376-40385. 2011
    2011 Hedgehog signaling pathway regulates the growth of ovarian cancer spheroid forming cellsInternational Journal of Oncology.  39:797-804. 2011
    2011 Hedgehog signaling: Networking to nurture a promalignant tumor microenvironmentCell Growth and Differentiation.  9:1165-1174. 2011
    2011 Hedgehog signaling induced by breast cancer cells promotes osteoclastogenesis and osteolysisJournal of Biological Chemistry.  286:9612-9622. 2011
    2011 Recent advances in anti-angiogenic therapy of cancerOncotarget.  2:122-134. 2011
    2010 Mechanisms of transcriptional regulation and prognostic significance of activated leukocyte cell adhesion molecule in cancerMolecular Cancer.  9. 2010
    2010 DNAJB6 induces degradation of β-catenin and causes partial reversal of mesenchymal phenotypeJournal of Biological Chemistry.  285:24686-24694. 2010
    2010 Functional characterization of the progestagen-associated endometrial protein gene in human melanomaJournal of Cellular and Molecular Medicine.  14:1432-1442. 2010
    2010 Spheroid-forming subpopulation of breast cancer cells demonstrates vasculogenic mimicry via hsa-miR-299-5p regulated de novo expression of osteopontinJournal of Cellular and Molecular Medicine.  14:1693-1706. 2010
    2010 Osteopontin: An effector and an effect of tumor metastasisCurrent Molecular Medicine.  10:71-81. 2010
    2010 Elevated osteopontin levels in metastatic melanoma correlate with epigenetic silencing of breast cancer metastasis suppressor 1Oncology.  78:75-86. 2010
    2009 Expression and functional analysis of the WAP four disulfide core domain 1 gene in human melanomaClinical and Experimental Metastasis.  26:739-749. 2009
    2009 The hedgehog pathway transcription factor GLI1 promotes malignant behavior of cancer cells by up-regulating osteopontinJournal of Biological Chemistry.  284:22888-22897. 2009
    2009 Multi-faceted role of HSP40 in cancerClinical and Experimental Metastasis.  26:559-567. 2009
    2009 Nmi (N-Myc interactor) inhibits Wnt/β-catenin signaling and retards tumor growthInternational Journal of Cancer.  125:556-564. 2009
    2009 Current concepts in biobanking: Development and implementation of a tissue repositoryFrontiers in bioscience (Scholar edition).  1 S:188-193. 2009
    2009 Microparticles/Exosomes: Isolation and TEM AnalysisMicroscopy Today.  17:42-45. 2009
    2009 Emerging role of nuclear protein 1 (NUPR1) in cancer biologyCancer and Metastasis Reviews.  28:225-232. 2009
    2008 Epigenetic silencing contributes to the loss of BRMS1 expression in breast cancerClinical and Experimental Metastasis.  25:753-763. 2008
    2008 Lung endothelial cells express ALCAM on released exosomes/microparticlesMicroscopy and Microanalysis.  14:1520-1521. 2008
    2008 NUPR1 interacts with p53, transcriptionally regulates p21 and rescues breast epithelial cells from doxorubicin-induced genotoxic stressCurrent Cancer Drug Targets.  8:421-430. 2008
    2008 Quantum dots - Utilization in TEMMicroscopy and Microanalysis.  14:702-703. 2008
    2008 Is N-cadherin expression important in ductal carcinoma?Southern Medical Journal.  101:470-475. 2008
    2008 The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis.BMC Medical Genomics.  1:13. 2008
    2008 Elevated levels of Ser/Thr protein phosphatase 5 (PP5) in human breast cancerBBA - Molecular Basis of Disease.  1782:259-270. 2008
    2008 Large isoform of MRJ (DNAJB6) reduces malignant activity of breast cancerBreast Cancer Research.  10. 2008
    2008 BRMS1Targeted Protein Database 1.  22093. 2008
    2008 Global comparative gene expression analysis of melanoma patient samples, derived cell lines and corresponding tumor xenograftsCancer Genomics and Proteomics.  5:1-35. 2008
    2007 Rac1 activity regulates proliferation of aggressive metastatic melanomaExperimental Cell Research.  313:3832-3839. 2007
    2007 Identification of differentially secreted biomarkers using LC-MS/MS in isogenic cell lines representing a progression of breast cancerJournal of Proteome Research.  6:2993-3002. 2007
    2007 Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-κB activationMolecular Cancer.  6. 2007
    2006 Breast cancer metastasis suppressor 1 (BRMS1) is stabilized by the Hsp90 chaperoneBiochemical and Biophysical Research Communications.  348:1429-1435. 2006
    2006 Suppression of murine mammary carcinoma metastasis by the murine ortholog of breast cancer metastasis suppressor 1 (Brms1)Cancer Letters.  235:260-265. 2006
    2006 Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435Clinical and Experimental Metastasis.  23:123-133. 2006
    2004 A small molecule antagonist of the αυβ 3 integrin suppresses MDA-MB-435 skeletal metastasisClinical and Experimental Metastasis.  21:119-128. 2004
    2004 Breast Cancer Metastasis Suppressor 1 (BRMS1) Forms Complexes with Retinoblastoma-binding Protein 1 (RBP1) and the mSin3 Histone Deacetylase Complex and Represses TranscriptionJournal of Biological Chemistry.  279:1562-1569. 2004
    2003 Metastasis suppressor pathways - An evolving paradigmCancer Letters.  198:1-20. 2003
    2002 Cu/Zn superoxide dismutase plays a role in angiogenesisInternational Journal of Cancer.  97:34-41. 2002
    2002 Identification and characterization of the murine ortholog (brms1) of breast-cancer metastasis suppressor 1 (BRMS1).International Journal of Cancer.  97:15-20. 2002
    2002 Suppression of human melanoma metastasis by the metastasis suppressor gene, BRMS1Experimental Cell Research.  273:229-239. 2002
    2001 Analysis of mechanisms underlying BRMS1 suppression of metastasisClinical and Experimental Metastasis.  18:683-693. 2001
    1999 Immune functions, clinical parameters and hormone receptor status in breast cancer patientsJournal of Cancer Research and Clinical Oncology.  125:313-320. 1999
    1998 Impaired T lymphocyte function and differential cytokine response pattern in members from cancer familiesNatural Immunity.  16:146-156. 1998
    1998 Studies on functional status of circulating lymphocytes in unaffected members from cancer familiesHuman Immunology.  59:373-381. 1998
    1998 Natural killer cell function and genetic instability in unaffected individuals from breast cancer familiesEuropean Journal of Cancer Prevention.  7:141-148. 1998

    Education And Training

  • Doctor of Philosophy Level Degree in Biology, University of Mumbai 1999
  • Full Name

  • Lalita Samant